Research Article

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population

Table 1

Comparison of eligible patients for DAPA-HF and EMPEROR-reduced, compared to patients receiving trial drug in respective trial.

CharacteristicUmeå cohort eligible for DAPA-HF ()DAPA-HF population
()
Umeå cohort eligible for EMPEROR-reduced ()EMPEROR-reduced population ()
value value

Age-yr79.0 (±10.0)66.2 (±11)<.00180.3 (±9.8)67.2 (±10.8)<.001
Female sex-no. (%)119 (33.8)564 (23.8)<.00193 (34.7)437 (23.5)
Body-mass index-kg/m226.4 (±4.9)28.2 (±6.0)<.00126.3 (±4.8)28.0 (±5.5)<.001
Heart rate-beats/min75.6 (±17.2)71.5 (±11.8)<.00176.3 (±17.0)71.0 (±11.7)<.001
Systolic blood pressure-mmHg124 (±18.2)122 (±11.8).026126 (±18.0)123 (±15.9).002
Left ventricle ejection fraction-%32.4 (±6.8)31.2 (±6.7).00230.1 (±6.7)27.7 (±6.0)<.001
Median NT-proBNP-ng/ml (IQR)1943 (1138-3562)1428 (857-2655)2897 (1607-4872)1887 (1077-3429)
eGFR-ml/min/1.73 m254.4 (±15.0)66 (±19.6)<.00149.5 (±17.8)61.8 (±21.7)<.001
Rate of eGFR <60 ml/min/1.73 m2-no./total no. (%)239/352 (67.9%)962/2372 (40.6)<.001198/268 (73.9)893/1862 (48.0)<.001
Hospitalization for heart failure-no. (%)182 (51.7)1124 (47.4).14175 (65.3)
Atrial fibrillation-no. (%)198 (56.3)916 (38.6)<.001142 (53.0)664 (35.6)<.001
Diabetes mellitus-no. (%)74 (21.0)993 (41.8)<.00170 (26.1)927 (49.8)<.001
Hypertension-no. (%)222 (63.1)n/a182 (67.9)1349 (72.4).15
Ischemic etiology-no. (%)163 (46.3)1316 (55.5).002130 (48.5)983 (52.8).22
Heart failure treatment
ACE-inhibitor or ARB-no. (%)258 (73.3)2007 (84.6)<.001195 (72.8)1314 (70.5).50
ARNI-No. (%)63 (17.9)250 (10.5)<.00150 (18.7)340 (18.3).94
MRA-no. (%)213 (60.5)1696 (71.5)<.001167 (62.3)1306 (70.1).012
Beta blocker-no. (%)322 (91.5)2278 (96.0)<.001244 (91)1765 (94.7).014
Diuretic-no. (%)233 (66.2)2216 (93.4)<.001204 (76.1)n/a
Digitalis-No (%)52 (14.8)445 (18.8).08436 (13.4)n/a
ICD-no. (%)47 (13.4)622 (26.6)<.00138 (14.2)578 (31.0)<.001
CRT-no. (%)53 (15.1)190 (8.0)<.00146 (17.2)220 (11.8).02

Number in parentheses is ±1 standard deviation; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor blocker and neprilysin inhibitor; MRA: mineral corticoid antagonist; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy. BMI available for 333/352 patients. BMI available for 255/268 patients. DAPA-HF reports prior HF hospitalization, and EMPEROR-reduced reports hospitalizations in the last 12 months.